The Dermatology Digest covers a study pairing the psoriasis biologic with tirzepatide, reporting bigger biomarker shifts from the combination.
Recap by typeshit. Full story at The Dermatology Digest.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Investor Lupton argues Hims & Hers and NURS.V stand to benefit most if regulators move peptides back to category 1. This is his own view as an investor, not a regulatory decision.
Pink Sheet editors say FDA reviewers warn the peptides lack clinical testing, and some career staff may quit if the order goes ahead.
Loading…